$STRO
SUTRO BIOPHARMA, INC. Stock $stro

$stro Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-K Financial Statement

#000156459020010890 Filed on March 16, 2020

Income Statement

Concept	2020 Q1	2019 Q4	2019 Q3
Revenue	$7.152M	$11.31M	$12.28M
YoY Change	-17.12%	-40.77%	56.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.710M	$8.700M	$8.120M
YoY Change	12.82%	14.93%	51.78%
% of Gross Profit
Research & Development	$17.62M	$17.39M	$16.90M
YoY Change	16.07%	17.58%	33.66%
% of Gross Profit
Depreciation & Amortization	$1.099M	$1.220M	$1.230M
YoY Change	-3.34%	7.02%	10.81%
% of Gross Profit
Operating Expenses	$17.62M	$26.09M	$25.01M
YoY Change	-23.04%	16.68%	39.01%
Operating Profit			-$12.74M
YoY Change			25.38%
Interest Expense	-$420.0K	-$10.00K	-$180.0K
YoY Change	-2200.0%	-101.41%	-143.37%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$19.60M	-$14.79M	-$12.91M
YoY Change	37.54%	892.62%	26.07%
Income Tax
% Of Pretax Income
Net Earnings	-$19.60M	-$14.79M	-$12.91M
YoY Change	37.51%	890.56%	26.13%
Net Earnings / Revenue	-273.98%	-130.82%	-105.17%
Basic Earnings Per Share	-$0.84		-$0.56
Diluted Earnings Per Share	-$0.84	-$640.5K	-$0.56
COMMON SHARES
Basic Shares Outstanding	23.10M		22.95M
Diluted Shares Outstanding			22.95M

Balance Sheet

Concept	2020 Q1	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$115.4M	$117.9M	$125.2M
YoY Change	-32.36%	-42.35%	1.79%
Cash & Equivalents	$43.57M	$4.960M	$11.95M
Short-Term Investments	$71.80M	$112.9M	$113.2M
Other Short-Term Assets	$3.000M	$4.400M	$2.900M
YoY Change	15.38%	46.67%	45.0%
Inventory
Prepaid Expenses
Receivables	$9.100M	$6.298M	$7.531M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$127.5M	$128.6M	$135.6M
YoY Change	-27.76%	-38.76%	6.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.500M	$9.633M	$8.522M
YoY Change	-4.04%	-11.9%	-26.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$14.20M	$15.60M	$25.20M
YoY Change	3.65%
Other Assets	$2.700M	$2.545M	$2.351M
YoY Change	20.81%	13.41%	-60.59%
Total Long-Term Assets	$26.40M	$27.80M	$36.11M
YoY Change	1.7%	110.73%	104.55%
TOTAL ASSETS
Total Short-Term Assets	$127.5M	$128.6M	$135.6M
Total Long-Term Assets	$26.40M	$27.80M	$36.11M
Total Assets	$153.9M	$156.4M	$171.7M
YoY Change	-23.98%	-29.92%	18.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.800M	$5.584M	$4.549M
YoY Change	70.84%	82.42%	-0.98%
Accrued Expenses	$2.900M	$6.017M	$4.628M
YoY Change	15.91%	-3.22%	13.29%
Deferred Revenue		$19.47M	$20.25M
YoY Change		-9.78%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.000M	$5.800M
YoY Change	-100.0%	-78.72%	81.25%
Total Short-Term Liabilities	$32.00M	$32.97M	$35.86M
YoY Change	2.79%	-9.49%	-2.83%
LONG-TERM LIABILITIES
Long-Term Debt	$24.20M	$8.876M	$5.500M
YoY Change	184.71%	-11.24%	-52.17%
Other Long-Term Liabilities	$15.60M	$134.0K	$129.0K
YoY Change	-51.4%	31.37%	-80.57%
Total Long-Term Liabilities	$39.80M	$9.010M	$5.629M
YoY Change	-1.97%	-10.81%	-53.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$32.00M	$32.97M	$35.86M
Total Long-Term Liabilities	$39.80M	$9.010M	$5.629M
Total Liabilities	$71.80M	$58.58M	$61.77M
YoY Change	0.14%	-36.05%	-37.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$215.3M	-$195.7M	-$181.0M
YoY Change	39.58%	30.21%	21.58%
Common Stock	$297.4M	$293.4M	$290.6M
YoY Change	4.38%	4.06%	3812.75%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$82.09M	$97.79M	$109.9M
YoY Change
Total Liabilities & Shareholders Equity	$153.9M	$156.4M	$171.7M
YoY Change	-24.0%	-29.92%	18.38%

Cashflow Statement

Concept	2020 Q1	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$19.60M	-$14.79M	-$12.91M
YoY Change	37.51%	890.56%	26.13%
Depreciation, Depletion And Amortization	$1.099M	$1.220M	$1.230M
YoY Change	-3.34%	7.02%	10.81%
Cash From Operating Activities	-$18.73M	-$13.15M	-$16.12M
YoY Change	-7.0%	121.38%	-133.88%
INVESTING ACTIVITIES
Capital Expenditures	$763.0K	-$2.050M	-$660.0K
YoY Change	176.45%	156.25%	83.33%
Acquisitions
YoY Change
Other Investing Activities	$42.40M	$9.990M	$10.48M
YoY Change	-154.5%	253.0%	-112.87%
Cash From Investing Activities	$41.64M	$7.940M	$9.820M
YoY Change	-153.33%	291.13%	-112.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	15.70M	-1.780M	-1.120M
YoY Change	-3528.38%	-102.03%	-102.23%
NET CHANGE
Cash From Operating Activities	-18.73M	-13.15M	-16.12M
Cash From Investing Activities	41.64M	7.940M	9.820M
Cash From Financing Activities	15.70M	-1.780M	-1.120M
Net Change In Cash	38.61M	-6.990M	-7.420M
YoY Change	-139.12%	-108.33%	-146.58%
FREE CASH FLOW
Cash From Operating Activities	-$18.73M	-$13.15M	-$16.12M
Capital Expenditures	$763.0K	-$2.050M	-$660.0K
Free Cash Flow	-$19.50M	-$11.10M	-$15.46M
YoY Change	-4.52%	115.95%	-132.25%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-109001000
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125298000
CY2018Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	79194000
CY2018Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	959000
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	847000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36423000
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	44599000
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	476000
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	212000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97789000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150328000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	131539000
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	223139000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38419000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	51741000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	54639000
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22848184
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22848184
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	281891000
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-47000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7272
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5457
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.5652
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7489
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.6238
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.5855
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0267
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0189
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0142
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80190000
CY2019	us-gaap	Substantial Doubt About Going Concern Within One Year SubstantialDoubtAboutGoingConcernWithinOneYear	false
CY2019	stro	Period For Cumulative Ownership Change PeriodForCumulativeOwnershipChange	P3Y
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0311
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0218
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	001-38662
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-0926186
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	310 Utah Avenue
CY2019	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2019	dei	City Area Code CityAreaCode	650
CY2019	dei	Local Phone Number LocalPhoneNumber	392-8412
CY2019	dei	Security12b Title Security12bTitle	Common stock, $0.001 par value
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019Q2	dei	Entity Public Float EntityPublicFloat	235600000
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23098969
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4960000
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	112904000
CY2019Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	1050000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6298000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2489000
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4406000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2965000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	128568000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	209946000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9633000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10934000
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15609000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2545000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2244000
CY2019	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1260000
CY2019	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	22536000
CY2019	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-4350000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Assets Assets	156370000
CY2018Q4	us-gaap	Assets Assets	223139000
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5584000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3061000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6017000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6217000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19465000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21574000
CY2019Q4	us-gaap	Debt Current DebtCurrent	1000000
CY2018Q4	us-gaap	Debt Current DebtCurrent	4724000
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	901000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	32967000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16195000
CY2019Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	409000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	8876000
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	10000000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	134000
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	102000
CY2019Q4	us-gaap	Liabilities Liabilities	58581000
CY2018Q4	us-gaap	Liabilities Liabilities	91600000
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23098969
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23098969
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	23000
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	293346000
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	165000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195745000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	97789000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	156370000
CY2018	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	290000
CY2017	stro	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	-689000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	865000
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-47000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-19688000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-90901000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	95000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1391000
CY2017	stro	Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares	86000
CY2017	stro	Interest On Note Receivable From Stockholder InterestOnNoteReceivableFromStockholder	1000
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	17000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-19688000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	734000
CY2018	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	187244000
CY2018	stro	Stock Issued During Period Value Preferred Stock Warrants Exercised Value StockIssuedDuringPeriodValuePreferredStockWarrantsExercisedValue	268000
CY2018	stro	Stock Issued During Period Value Stock Options And Warrants Exercised StockIssuedDuringPeriodValueStockOptionsAndWarrantsExercised	134000
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	74436000
CY2018	stro	Stock Issued During Period Value With Private Placement StockIssuedDuringPeriodValueWithPrivatePlacement	10000000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2872000
CY2018	stro	Adjustments To Additional Paid In Capital Vesting Of Early Exercise Of Shares AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExerciseOfShares	8000
CY2018	stro	Payment Of Note Receivable By Stockholder PaymentOfNoteReceivableByStockholder	208000
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	131539000
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	180000
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1260000
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	297000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10312000
CY2019	us-gaap	Profit Loss ProfitLoss	-55744000
CY2018	us-gaap	Profit Loss ProfitLoss	-35317000
CY2017	us-gaap	Profit Loss ProfitLoss	-19688000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4777000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4539000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4990000
CY2019	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	1457000
CY2018	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	527000
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-106000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	10312000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	2872000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1391000
CY2018	stro	Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability RevaluationOfRedeemableConvertiblePreferredStockWarrantLiability	-973000
CY2017	stro	Revaluation Of Redeemable Convertible Preferred Stock Warrant Liability RevaluationOfRedeemableConvertiblePreferredStockWarrantLiability	186000
CY2019	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	115000
CY2018	us-gaap	Unrealized Gain Loss On Derivatives And Commodity Contracts UnrealizedGainLossOnDerivativesAndCommodityContracts	854000
CY2019	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-275000
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-193000
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-337000
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-103000
CY2017	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	2742000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3809000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1047000
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1441000
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2220000
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	354000
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2253000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	209000
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-200000
CY2017	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-86000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	42305000
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-25566000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-65023000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	12683000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37073000
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	196226000
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	81463000
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	14220000
CY2019	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	128576000
CY2018	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	2750000
CY2017	stro	Proceeds From Maturities Of Marketable Securities ProceedsFromMaturitiesOfMarketableSecurities	34850000
CY2019	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	20000000
CY2017	stro	Proceeds From Sales Of Marketable Securities ProceedsFromSalesOfMarketableSecurities	15208000
CY2019	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	3481000
CY2018	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	1557000
CY2017	stro	Payments To Acquire Equipment And Leasehold Improvements PaymentsToAcquireEquipmentAndLeaseholdImprovements	3316000
CY2018	stro	Proceeds From Exercise Of Options For Sutrovax Shares ProceedsFromExerciseOfOptionsForSutrovaxShares	80000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51131000
CY2019	us-gaap	Repayments Of Debt RepaymentsOfDebt	5000000
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15000000
CY2017	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	170000
CY2019	stro	Proceeds From Issuance Of Common Stock Options And Common Stock Warrants ProceedsFromIssuanceOfCommonStockOptionsAndCommonStockWarrants	180000
CY2018	stro	Proceeds From Issuance Of Common Stock Options And Common Stock Warrants ProceedsFromIssuanceOfCommonStockOptionsAndCommonStockWarrants	134000
CY2017	stro	Proceeds From Issuance Of Common Stock Options And Common Stock Warrants ProceedsFromIssuanceOfCommonStockOptionsAndCommonStockWarrants	95000
CY2019	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	297000
CY2018	us-gaap	Proceeds From Issuance Of Redeemable Convertible Preferred Stock ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock	84739000
CY2018	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	74436000
CY2019	stro	Payment Of Offering Costs PaymentOfOfferingCosts	327000
CY2017	stro	Payment Of Offering Costs PaymentOfOfferingCosts	286000
CY2018	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10000000
CY2018	stro	Proceeds From Preferred Stock Warrants Exercises ProceedsFromPreferredStockWarrantsExercises	268000
CY2018	stro	Proceeds From A Research Development And Commercialization Agreement ProceedsFromAResearchDevelopmentAndCommercializationAgreement	1000000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4184000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	170785000
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-120338000
CY2017Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	22035000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195700000
CY2019Q4	stro	Unrestricted Cash Cash Equivalents And Marketable Securities At Carrying Value UnrestrictedCashCashEquivalentsAndMarketableSecuritiesAtCarryingValue	133500000
CY2019Q4	us-gaap	Liabilities Liabilities	58581000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-195745000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	125313000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	22035000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1049000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1275000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	479000
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	270000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	205000
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	255000
CY2017	stro	Offering Costs Included In Accounts Payable OfferingCostsIncludedInAccountsPayable	259000
CY2019	stro	Embedded Interest Associated With Program Fees EmbeddedInterestAssociatedWithProgramFees	3144000
CY2018	stro	Vesting Of Early Exercised Shares VestingOfEarlyExercisedShares	8000
CY2017	stro	Vesting Of Early Exercised Shares VestingOfEarlyExercisedShares	86000
CY2018	stro	Conversion Of Redeemable Convertible Preferred Stock And Warrants Into Common Stock Upon Ipo Net Of Issuance Costs ConversionOfRedeemableConvertiblePreferredStockAndWarrantsIntoCommonStockUponIPONetOfIssuanceCosts	187244000
CY2018	stro	Reclassification Of Redeemable Convertible Preferred Stock Warrant Liability To Equity ReclassificationOfRedeemableConvertiblePreferredStockWarrantLiabilityToEquity	734000
CY2019	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top:13pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-family:Arial;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.Organization and Principal Activities</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-family:Arial;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sutro Biopharma, Inc. (the “Company”) is a clinical stage drug discovery, development and manufacturing company focused on leveraging its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF<sup style="font-size:85%;line-height:120%;vertical-align:top">®</sup>, to create a broad variety of optimally designed, next-generation protein therapeutics for cancer and autoimmune disorders. The Company was incorporated on April 21, 2003, and is headquartered in South San Francisco, California. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one business segment, the development of biopharmaceutical products. <span style="font-size:12pt;"> </span> <span style="font-size:12pt;"> </span></p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Liquidity </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has incurred significant losses and has negative cash flows from operations. As of December 31, 2019, there was an accumulated deficit of $195.7 million. Management expects to continue to incur additional substantial losses in the foreseeable future as a result of the Company’s research and development activities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the Company had unrestricted cash, cash equivalents and marketable securities of $133.5 million, which is available to fund future operations. The Company will need to raise additional capital to support the completion of its research and development activities and its operations.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:2.86%;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 28, 2020, the Company entered into a loan and security agreement (the “Loan and Security Agreement”) with Oxford Finance LLC (“Oxford”), as the collateral agent and a lender, and Silicon Valley Bank, as a lender (together with Oxford, the “Lenders”), pursuant to which the Lenders have agreed to lend the Company up to an aggregate of $25.0 million in a series of term loans (the “Term A Loan”). Upon entering into the Loan and Security Agreement, the Company borrowed $25.0 million from the Lenders, with approximately $9.6 million of such amount applied to the repayment of the outstanding principal, interest and final payment fees owed pursuant to a prior loan and security agreement dated August 4, 2017 with the Lenders. Under the terms of the Loan and Security Agreement, the Company may, at its sole discretion, borrow from the Lenders up to an additional $5.0 million upon the closing of a new collaboration agreement that includes an upfront payment of at least $50.0 million to the Company<span style="color:#000000;">, as determined by Oxford in its sole and absolute discretion</span>. The proceeds from the Term Loans under the Loan and Security Agreement may be used to satisfy the Company’s future working capital needs and to fund its general business requirements. Please see an expanded discussion on the Loan and Security Agreement in Note 15 Subsequent Events.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company believes that its unrestricted cash, cash equivalents and marketable securities as of December 31, 2019 will enable the Company to maintain its operation for a period of at least 12 months following the filing date of its financial statements. </p>
CY2019	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2003-04-21
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42700000
CY2018Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	2489000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	209946000
CY2018Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	21574000
CY2018Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	44599000
CY2018Q4	us-gaap	Liabilities Liabilities	91600000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-150328000
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	19465000
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	16195000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	42736000
CY2019	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4350000
CY2019	us-gaap	Profit Loss ProfitLoss	-55744000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	168000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4960000
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	125298000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	22020000
CY2019Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	15000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4975000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125313000
CY2019	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:0pt;text-indent:2.86%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Arial;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk, to the extent of the amounts recorded on the balance sheets. The Company minimizes the amount of credit exposure by investing cash that is not required for immediate operating needs in money market funds, government obligations and/or commercial paper with short maturities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.64%;font-size:10pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company regularly reviews the outstanding accounts receivable, including consideration of factors such as the age of the receivable balance. As of December 31, 2019 and 2018, there was no allowance for doubtful accounts deemed necessary. As of December 31, 2019 and 2018, the Company’s accounts receivable balances were entirely attributable to the Company’s collaboration agreements. </p>
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2019	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2018	us-gaap	Impairment Of Long Lived Assets To Be Disposed Of ImpairmentOfLongLivedAssetsToBeDisposedOf	0
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	19500000
CY2019Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2019Q4	stro	Convertible Preferred Stock Warrant Liability Fair Value ConvertiblePreferredStockWarrantLiabilityFairValue	100000
CY2019	stro	Deemed Dividend DeemedDividend	0
CY2018Q4	stro	Convertible Preferred Stock Warrant Liability Fair Value ConvertiblePreferredStockWarrantLiabilityFairValue	100000
CY2018	stro	Deemed Dividend DeemedDividend	0
CY2017	stro	Deemed Dividend DeemedDividend	0
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	131499000
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	3000
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	131664000
CY2019Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	15600000
CY2018Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0
CY2019Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	4500000
CY2018Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	52600000
CY2019	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2018	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6966000
CY2019	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	3600000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	43481000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	33848000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9633000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10934000
CY2019	us-gaap	Interest Expense Debt InterestExpenseDebt	1100000
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	1600000
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	600000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3771000
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3195000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2200000
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2300000
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1600000
CY2019	us-gaap	Common Stock Voting Rights CommonStockVotingRights	one vote per share
CY2019Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	7357234
CY2018Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6250381
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.71
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	7.26
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1100000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.038
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.013
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.005
CY2019	stro	Effective Income Tax Rate Reconciliation Asc606 Adoption Percent EffectiveIncomeTaxRateReconciliationASC606AdoptionPercent	-0.039
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.227
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.047
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.327
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.208
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.049
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.075
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10312000
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2872000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1391000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.634
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.020
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.048
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2018	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	251000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3783000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2795000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2305000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019Q4	stro	Tax Cuts And Jobs Act Of2017 Change In Deferred Tax Assets And Valuation Allowance TaxCutsAndJobsActOf2017ChangeInDeferredTaxAssetsAndValuationAllowance	-12300000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	31010000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	29296000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	20098000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	15680000
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	7680000
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	3027000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3718000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	2342000
CY2019Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	795000
CY2018Q4	stro	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	363000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63301000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	50708000
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	63301000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	50708000
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12600000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	11600000
CY2019	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	Events which cause limitations in the amount of net operating losses that the Company may utilize in any one year include, but are not limited to, a cumulative ownership change of more than 50%, as defined, over a three-year testing period.
CY2019Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	3800000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2800000
CY2017Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	2300000
CY2019	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2795000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2305000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1635000
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1005000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	741000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	670000
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	17000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-1493000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-55744000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-35317000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-19688000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22958577
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	5758875
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	447946
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.13
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-43.95
CY2019	stro	Net Loss Per Share NetLossPerShare	0
CY2018	stro	Net Loss Per Share NetLossPerShare	0
CY2017	stro	Net Loss Per Share NetLossPerShare	9889
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4321697
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3524187
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5995724
CY2019Q4	us-gaap	Revenues Revenues	11305000
CY2019Q3	us-gaap	Revenues Revenues	12277000
CY2019Q2	us-gaap	Revenues Revenues	10525000
CY2019Q1	us-gaap	Revenues Revenues	8629000
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-14789000
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-12912000
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-13793000
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-14250000
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.65
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.60
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2018Q4	us-gaap	Revenues Revenues	19086000
CY2018Q3	us-gaap	Revenues Revenues	7836000
CY2018Q2	us-gaap	Revenues Revenues	5704000
CY2018Q1	us-gaap	Revenues Revenues	5793000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-10237000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-11541000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-12046000
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-21.26
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-24.17
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-25.76

Files In Submission

Name	View Source	Status
0001564590-20-010890-index-headers.html	Edgar Link	pending
0001564590-20-010890-index.html	Edgar Link	pending
0001564590-20-010890.txt	Edgar Link	pending
0001564590-20-010890-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g1qggngdd0um000001.jpg	Edgar Link	pending
gog2fbdpw2dp000001.jpg	Edgar Link	pending
gog2fbdpw2dp000002.jpg	Edgar Link	pending
gog2fbdpw2dp000003.jpg	Edgar Link	pending
gog2fbdpw2dp000004.jpg	Edgar Link	pending
gog2fbdpw2dp000005.jpg	Edgar Link	pending
gog2fbdpw2dp000006.jpg	Edgar Link	pending
gog2fbdpw2dp000007.jpg	Edgar Link	pending
gog2fbdpw2dp000008.jpg	Edgar Link	pending
gog2fbdpw2dp000009.jpg	Edgar Link	pending
gog2fbdpw2dp000010.jpg	Edgar Link	pending
gog2fbdpw2dp000011.jpg	Edgar Link	pending
gog2fbdpw2dp000012.jpg	Edgar Link	pending
gog2fbdpw2dp000013.jpg	Edgar Link	pending
gog2fbdpw2dp000014.jpg	Edgar Link	pending
gog2fbdpw2dp000015.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stro-10k_20191231.htm	Edgar Link	pending
stro-10k_20191231_htm.xml	Edgar Link	completed
stro-20191231.xsd	Edgar Link	pending
stro-20191231_cal.xml	Edgar Link	unprocessable
stro-20191231_def.xml	Edgar Link	unprocessable
stro-20191231_lab.xml	Edgar Link	unprocessable
stro-20191231_pre.xml	Edgar Link	unprocessable
stro-ex1020_294.htm	Edgar Link	pending
stro-ex1021_394.htm	Edgar Link	pending
stro-ex1022_393.htm	Edgar Link	pending
stro-ex231_10.htm	Edgar Link	pending
stro-ex311_14.htm	Edgar Link	pending
stro-ex312_13.htm	Edgar Link	pending
stro-ex321_8.htm	Edgar Link	pending
stro-ex322_12.htm	Edgar Link	pending
stro-ex45_62.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STRO
SUTRO BIOPHARMA, INC. Stock $stro

2020 Q1 Form 10-K Financial Statement

#000156459020010890 Filed on March 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO SUTRO BIOPHARMA, INC. Stock $stro

2020 Q1 Form 10-K Financial Statement

#000156459020010890 Filed on March 16, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STRO
SUTRO BIOPHARMA, INC. Stock $stro